Retrospective Study of the Use of Everolimus/Exemestane in the Treatment of Oestrogen Receptor Positive (ER plus ) Metastatic Breast Cancer (MBC): The Kent Oncology Network Experience

被引：0
|
作者：
Ang, J. E. [1 ]
Jyothirmayi, R. [1 ]
Mithal, N. [1 ]
Abson, C. [1 ]
Burcombe, R. [1 ]
Harper-Wynne, C. [1 ]
机构：
[1] Kent Oncol Ctr, Maidstone, Kent, England
来源：
CLINICAL ONCOLOGY | 2015年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E9 / E9
页数：1
相关论文
共 50 条
  • [21] Acquired RBI mutations in estrogen receptor-positive (ER plus ) clinically advanced and metastatic breast cancer (MBC).
    McGregor, Kimberly
    Sokol, Ethan
    Danziger, Natalie
    Pavlick, Dean
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Jonathan Keith
    Lin, Douglas I.
    Williams, Erik Abraham
    Ramkissoon, Shakti H.
    Severson, Eric Allan
    Hemmerich, Amanda
    Duncan, Daniel
    Huang, Richard
    Chung, Jon
    Reddy, Venkataprasanth P.
    Venstrom, Jeffrey
    Schrock, Alexa Betzig
    Alexander, Brian Michael
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
    Mayer, Erica L.
    Tolaney, Sara M.
    Brufsky, Adam
    Gradishar, William John
    Jhaveri, Komal L.
    Martin, Miguel
    Moscetti, Luca
    Schneeweiss, Andreas
    Vidal, Gregory A.
    Cortazar, Patricia
    Feldman, Merilin
    Day, Bann-mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A COST-UTILITY ANALYSIS OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF ER+HER2-METASTATIC BREAST CANCER IN THE UNITED KINGDOM
    Taylor, M.
    Lewis, L.
    Vieira, J.
    Chandiwana, D.
    VALUE IN HEALTH, 2013, 16 (07) : A416 - A416
  • [24] Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
    Cook, Madeline M.
    Al Rabadi, Luai
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi I.
    ONCOLOGIST, 2021, 26 (02): : 101 - 106
  • [25] Outcomes of Everolimus plus Exemestane in ER-positive, HER2-negative Heavily Pre-treated Metastatic Breast Cancer Patients: A Real Life Multicentre Experience
    Desai, P.
    Hogg, M.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E42 - E43
  • [26] Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
    Kourlaba, Georgia
    Rapti, Vasiliki
    Alexopoulos, Athanasios
    Relakis, John
    Koumakis, Georgios
    Chatzikou, Magdalini
    Maniadakis, Nikos
    Georgoulias, Vassilis
    BMC HEALTH SERVICES RESEARCH, 2015, 15
  • [27] Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology Departments
    Meattini, I.
    Salvadori, B.
    Coltelli, L.
    Perna, M.
    Carta, G. A.
    Becherini, C.
    Grassi, R.
    Garlatti, P.
    Cappelli, S.
    Desideri, I.
    Vannini, A.
    Fontana, A.
    Landucci, E.
    Michelotti, A.
    Ricci, S.
    Allegrini, G.
    Falcone, A.
    Livi, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Incidence and management of toxicities associated with everolimus and exemestane (EVE plus EXE) in ER plus advanced breast cancer: The Royal Marsden experience
    Thanopoulou, E.
    Omarini, C.
    Patwari, S.
    Allen, M.
    Smith, I. E.
    Parton, M.
    O'Brien, M.
    Turner, N.
    Johnston, S. R. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S181
  • [29] Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
    Georgia Kourlaba
    Vasiliki Rapti
    Athanasios Alexopoulos
    John Relakis
    Georgios Koumakis
    Magdalini Chatzikou
    Nikos Maniadakis
    Vassilis Georgoulias
    BMC Health Services Research, 15
  • [30] Predictive markers of everolimus efficacy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study.
    Treilleux, Isabelle
    Arnedos, Monica
    Cropet, Claire
    Ferrero, Jean-Marc
    Lacourtoisie, Sophie Abadie
    Spaeth, Dominique
    Levy, Christelle
    Legouffe, Eric
    Pujade-Lauraine, Eric
    Wang, Quing
    Bachelot, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345